US Stock MarketDetailed Quotes

BBIO BridgeBio Pharma

Watchlist
  • 34.900
  • +3.340+10.58%
Close Feb 14 16:00 ET
  • 34.850
  • -0.050-0.14%
Post 19:57 ET
6.60BMarket Cap-14.42P/E (TTM)

BridgeBio Pharma Key Stats

BridgeBio Pharma Q4 2024 Estimates Date

Currency:USDFeb 20, 2025

Estimate YoY
Revenue
4.04M
+131.48%
EPS
-0.95
+1.55%
Strong Buy

Feb 17, 2025

BridgeBio Pharma Earnings Estimates

Revenue

EPS

EBIT

Revenue is based on 7 analyst forecasts. Estimate data is from S&P, and actual data is from Income Statement

Currency: USD

Actual
Estimate
DatePeriodRevenue/EstimateEarnings Call
--2025/Q1-- / 46.481M--
Feb 20, 20252024/Q4-- / 4.039M--
--2024/Q32.732M / 3.381M--
--2024/Q22.168M / 4.475M--
--2024/Q1211.120M / 83.777M--
DatePeriodRevenue/EstimateEarnings Call
--2025/Q1-- / 46.481M--
Feb 20, 20252024/Q4-- / 4.039M--
--2024/Q32.732M / 3.381M--
--2024/Q22.168M / 4.475M--
--2024/Q1211.120M / 83.777M--

Unlock Free Earnings Estimates

BridgeBio Pharma Earnings Reports

Read more

Trending Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries

Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.

Analysis

Analyst Rating

Updated: Feb 17, 2025

Strong Buy

  • Buy

    87.50%
  • Hold

    12.50%
  • Sell

    0.00%

Price Target

No Data